Erratum to: Acyclovir resistance in herpes simplex virus type I encephalitis: a case report

J. Neurovirol. (2017) 23:637 DOI 10.1007/s13365-017-0541-0 ERRATUM Erratum to: Acyclovir resistance in herpes simplex virus type I encephalitis: a case report M. Bergmann 1 & R. Beer 1 & M. Kofler 1 & R. Helbok 1 & B. Pfausler 1 & E. Schmutzhard 1 Published online: 29 June 2017 # Journal of NeuroVirology, Inc. 2017 Erratum to: J. Neurovirol. (2017) 23:335–337 DOI 10.1007/s13365-016-0489-5 We apologize for the mistake which slipped through all careful reading and re-reading: it must, correctly, read throughout the entire paper ... foscarnet i.v. 60 mg per kg bodyweight (b.w.), t.i.d. It is correct that 40 mg/kg b.w. is the recommended daily dose (Chilukuri and Rosen 2011), but in view of the dramatic clinical and neuro-imaging course we opted for an increased dose carefully monitoring for side effects. References Bergmann M, Beer R, Kofler M, Helbok R, Pfausler B, Schmutzhard E (2017) Acyclovir resistance in herpes simplex virus type I encephalitis: a case report. J Neurovirol 23(2):335–337 Chilukuri S, Rosen T (2003) Management of acyclovir-resistant herpes simplex virus. Dermatol Clin 21:311–320 The online version of the original article can be found at http://dx.doi.org/ 10.1007/s13365-016-0489-5 * E. Schmutzhard 1 Department of Neurology, Neurocritical Care Unit, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria  (...truncated)